80096-64-6

Usage

Uses

Used in Pharmaceutical Industry:
6-Hydroxy-chroman-4-one is used as a key intermediate in the synthesis of novel parasite transmission blocking antimalarials. These antimalarial agents are specifically designed to target male gametes, thereby disrupting the transmission of the malaria parasite and preventing the spread of the disease.
In the development of these novel antimalarials, 6-Hydroxy-chroman-4-one plays a crucial role in the chemical structure of the final product. Its unique properties and reactivity make it an ideal candidate for the creation of new drugs that can effectively combat malaria by targeting a previously unexplored aspect of the parasite's life cycle.
Furthermore, the use of 6-Hydroxy-chroman-4-one in the preparation of these antimalarials highlights its potential as a versatile building block in the pharmaceutical industry. Its ability to be modified and incorporated into various drug candidates makes it a valuable asset in the ongoing search for new and effective treatments for a wide range of diseases and conditions.

Upstream product

• 39223-40-0 3-(4-hydroxy-phenoxy)-propionic acid 
• 34985-50-7 4-methoxyphenyl 3-chloropropionate 
• 5802-17-5 6-methoxychroman-4-one 
• 625-36-5 2-chloropropionyl chloride 
• 108-46-3 recorcinol 
• 110704-60-4 5-fluoro-2-chloromethylbenzothiazole 
• 49660-57-3 6-bromochroman-4-one 
• 491-37-2 2,3-dihydro-4H-1-benzopyran-4-one 
• 1421659-47-3 2,3-dihydro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4H-1-benzopyran-4-one 
• 38445-24-8 6-hydroxy-4H-1-benzopyran-4-one 
• 123-31-9 hydroquinone 
• 90563-81-8 3-(4-hydroxyphenoxy)propionitrile 

Downstream Products

• 123094-61-1 6-benzyloxychroman-4-one 
• 1471989-14-6 6-tert-butyldiphenylsilyloxy-2,3-dihydro-4H-chromen-4-one 
• 176431-77-9 6-ethoxy-2,3-dihydro-4H-1-benzopyran-4-one 
• 1361926-67-1 6-[(4-fluorobenzyl)oxy]-4H-chromen-4-one 
• 1361926-63-7 6-[(4-chlorobenzyl)oxy]-4H-chromen-4-one 
• 4250-77-5 6-hydroxyflavanone 
• 251639-70-0 3-{6-benzyloxy-4-[2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionyloxy]-chroman-3-ylmethyl}-4-methoxy-benzoic acid methyl ester 
• 158102-93-3 CP-199,331 
• 251639-71-1 [3-((3R,4R)-6-Benzyloxy-4-hydroxy-chroman-3-ylmethyl)-4-methoxy-phenyl]-carbamic acid benzyl ester 
• 251639-72-2 (3R,4R)-3-(5-Amino-2-methoxy-benzyl)-6-(7-chloro-quinolin-2-ylmethoxy)-chroman-4-ol 
• 158102-89-7 3-((3R,4R)-6-Benzyloxy-4-hydroxy-chroman-3-ylmethyl)-4-methoxy-benzoic acid 
• 158102-86-4 3-(6-Benzyloxy-4-oxochroman-3-ylmethyl)-4-methoxybenzoic acid methyl ester 
• 158102-91-1 (3R,4R)-3-(5-Amino-2-methoxy-benzyl)-chroman-4,6-diol 

Relevant academic research and scientific papers

POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT

Described are polymerizable high energy light absorbing compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and X are as described herein. The compounds absorb various wavelengths of ultraviolet and/or high energy visible light and are suitable for incorporation in various products, such as biomedical devices and ophthalmic devices.

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

Chemoselective Hydrosilylation of the α,β-Site Double Bond in α,β- And α,β,γ,δ-Unsaturated Ketones Catalyzed by Macrosteric Borane Promoted by Hexafluoro-2-propanol

The B(C6F5)3-catalyzed chemoselective hydrosilylation of α,β- and α,β,γ,δ-unsaturated ketones into the corresponding non-symmetric ketones in mild reaction conditions is developed. Nearly 55 substrates including those bearing reducible functional groups such as alkynyl, alkenyl, cyano, and aromatic heterocycles are chemoselectively hydrosilylated in good to excellent yields. Isotope-labeling studies revealed that hexafluoro-2-propanol also served as a hydrogen source in the process.

Synthesis of Flavanones via Palladium(II)-Catalyzed One-Pot β-Arylation of Chromanones with Arylboronic Acids

A total of 47 flavanones were expediently synthesized via one-pot β-arylation of chromanones, a class of simple ketones possessing chemically unactivated β sites, with arylboronic acids via tandem palladium(II) catalysis. This reaction provides a novel route to various flavanones, including natural products such as naringenin trimethyl ether, in yields up to 92percent.

Transition metal free regio-selective C-H hydroxylation of chromanones towards the synthesis of hydroxyl-chromanones using PhI(OAc)2 as the oxidant

The chromanone scaffold is considered as a privileged structure in drug discovery. Herein, we report a highly efficient PhI(OAc)2 mediated regioselective, direct C-H hydroxylation of chromanones. This method offers easy access to substituted 6-hydroxy chromanones in moderate to good isolated yields, thus paving the way for their pharmaceutical studies.

Synthesis of Phenols: Organophotoredox/Nickel Dual Catalytic Hydroxylation of Aryl Halides with Water

A highly effective hydroxylation reaction of aryl halides with water under synergistic organophotoredox and nickel catalysis is reported. The OH group of the resulting phenols originates from water, following deprotonation facilitated by an intramolecular base group on the ligand. Significantly, aryl bromides as well as less reactive aryl chlorides served as effective substrates to afford phenols with a wide range of functional groups. Without the need for a strong inorganic base or an expensive noble-metal catalyst, this process can be applied to the efficient preparation of diverse phenols and enables the hydroxylation of multifunctional pharmaceutically relevant aryl halides.

a, ? UNSATURATED AMIDE COMPOUND

The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

Chroman Compound, Processes for Its Preparation, and Its Pharmaceutical Use

The present invention provided a chroman compound, the method of its preparation and pharmaceutical applications. The compound are represented by formula (I) and its pharmaceutical salt, where in :x is for O or S; n is for 2, 3 or 4; R1 is 6-situ or 7-situ halogen, C1-4alkyl, C1-4alkyoxyl, benzyloxy, acylamino; R2 is nitrogen-containing pentatomic or hexahydric substituted heterocyclic ring. The compound is useful to prepare anti-arrhythmic drugs, the reaction conditions of the method are mild, the raw material are plenty and easy to be obtained, and the operation and post-treatment are simple.

Inhibitors of prenyl-protein transferase

The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

MUSCARINIC ANTAGONISTS

Di-N-substituted piperazine or 1,4-di-substituted piperidine compounds in accordance with formula (I) (including all isomers, salts, esters, and solvates), wherein Q, n, R, R, R, R, R, R, R, R, X, and Z are as defined herein are mu